Oxycodone controlled-release - Intellipharmaceutics

Drug Profile

Oxycodone controlled-release - Intellipharmaceutics

Alternative Names: Abuse deterrent oxycodone hydrochloride extended release tablets - Intellipharmaceutics; Abuse-resistant oxycodone - Intellipharmaceutics; Oxycodone CR - Intellipharmaceutics; Rexista oxycodone

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intellipharmaceutics International
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 26 Jul 2017 The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee votes against the NDA approval for Rexista™ in Pain
  • 11 Jul 2017 A joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US FDA has been scheduled to review the NDA for Rexista™ abuse-deterrent oxycodone hydrochloride extended release tablets
  • 10 Apr 2017 Purdue Pharmaceuticals files patent infringement against Intellipharmaceutics with respect to NDA filing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top